Actinium Pharmaceuticals Inc at B Riley Securities Oncology Conference (Virtual) Transcript
All right. Good morning, everyone. Welcome to B. Riley Securities oncology conference on day two and listening to our fireside chat. I'm Yuan Zhi, a healthcare equity research analyst at B. Riley Securities. It is my great pleasure to have Sandesh Seth, CEO of Actinium Pharmaceuticals.
Thank you for joining us today, and congrats on a very productive 2022 and congrats on ringing the closing bell at NYSE today. Now we have some great news from this ARROW trial not a long ago, and it is exciting to see the full data will be presented as a late breaker at a tandem meeting on February 18 in Florida.
In addition to that, we also have an oral presentation at ASH conference from the Actimab program. Before we talk about this in detailed progress, Sandesh, maybe you can give the audience a quick overview of your clinical programs and the platform.
Yeah, sure. So thanks for having me, appreciate it. looking forward to the data on February 18. So company
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
